Clinical Trial Update: A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) [Phase 3]

View source ↗

Summary

A Phase 3 pilot trial evaluating subcutaneous immunoglobulin (SCIG) in patients with Myasthenia Gravis exacerbation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• SCIG (subcutaneous immunoglobulin)

Snippet

Sponsor: University of Alberta | Conditions: Myasthenia Gravis | Phase 3 | Status: COMPLETED